Author

Jesse L. Carlin

A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS
A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS

Jesse L. Carlin  et al.

EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301
EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301

Jesse L. Carlin  et al.

EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301
EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301

A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS
A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS

A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS
A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS

Jesse L. Carlin  et al.

EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301
EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301

Jesse L. Carlin  et al.

TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL
TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL

Jesse L. Carlin  et al.

TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL
TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL

Jesse L. Carlin

TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL
TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL

POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301
POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301

Jesse L. Carlin  et al.

Item 1 - 10 / 10
1